



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/775,262 | 02/01/2001 | James L. McMenimen | P-9153.02 | 7232 |

27581 7590 10/21/2002

MEDTRONIC, INC.
710 MEDTRONIC PARKWAY NE
MS-LC340
MINNEAPOLIS, MN 55432-5604

EXAMINER

JASMIN, LYNDIA C

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

3627

DATE MAILED: 10/21/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/775,262

Applicant(s)

MCMENIMEN ET AL.

Examiner

Lynda C Jasmin

Art Unit

3627

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 01 February 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 01 February 2001 is/are: a) ☐ accepted or b) ☒ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 8.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____

DETAILED ACTION

Drawings

1. The drawings are objected to as failing to comply with 37 CFR 1.84(p)(4) because reference character "60" has been used to designate both "outer housing" in Fig. 2 and "information network" in Fig. 3. A proposed drawing correction or corrected drawings are required in reply to the Office action to avoid abandonment of the application. The objection to the drawings will not be held in abeyance.

Specification

2. The abstract of the disclosure is objected to because it exceeds 150 words in length. Correction is required. See MPEP § 608.01(b).
3. The disclosure is objected to because of the following informalities: on pages 13 and 14 reference character 60 is referred as "housing" and on page 15, it is referred as "information network" consistency is required.

Appropriate correction is required.

Double Patenting

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225

Art Unit: 3627

USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-3 and 5-7 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-4 and 6-8 of copending Application No. 09/775,281 in view of Colligan et al. (6,298,443 B1). Copending application 09/775,281 discloses all the limitation of claims 1-3 and 5-7, except for the teaching of the implanted medical device having specific features including customized featured having customized data set. Colligan et al. discloses the concept of having a custom-programmed CD ROM that is configured for a specified individual computer system (with Service Tag number of the specified computer system) and constraint to be downloaded to and operable on only the specified individual computer system.

From this teaching of Colligan et al., it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the

Art Unit: 3627

implanted medical device management system and method of the copending applicant 09/775,281 to include the concept of the customized build-to-order software image to a computer system taught by Colligan et al. in order to fit customer's specific needs.

This is a provisional obviousness-type double patenting rejection.

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1-7 are rejected under 35 U.S.C. 103(a) as being unpatentable over Duffin et al. (5,752,976), in view of Colligan et al. (6,298,443 B1).

Duffin et al. discloses a medical device management system as claimed having a web-enabled information network (via 50), a programmer (via 20), at least one

Art Unit: 3627

implanted medical device having specific features (12, 14), deployed from a known source (physicians office or clinic). The web-enabled information network (50) is in bi-directional data communications scheme with the programmer (20) (col. 5, lines 31-37). The web-enabled information network (50) includes one of a satellite based telecommunications link and a cellular link (col. 6 lines 27-35). The at least one implanted medical device (12, 14) includes data relating to specific device functions and/or features for example a voice alert in the patient's own language (col. 10, lines 24-29), patient's name and identification number or name of the implanting institution and physician (col. 14, lines 39-47). The known source includes at least one of a hospital with data communications with the web-enabled information network (col. 5, lines 38-50).

However, Duffin et al. fails to disclose the implanted medical device having specific features including customized featured having customized data set downloadable to the web-information network to thereby route device information to the manufacturing facility to start a build-to-order/build-to-replenish operation, and in data communication with shipping/delivery and maintain an inventory.

Colligan et al. discloses the concept of having a build-to-order custom-programmed CD ROM that is configured for a specified individual computer system (with Service Tag number of the specified computer system) and constraint to be downloaded to and operable on only the specified individual computer system. Colligan et al. also discloses a software transport package manufacturing process (300) to retrieve customer order record by part number and a shipping method. Colligan et al.

Art Unit: 3627

further discloses the concept of maintain and inventory via an asset tag (col. 11, lines 24 and 25).

From this teaching of Colligan et al., it would have been obvious to one of ordinary skill in the art at the time the invention was made to have modified the implanted medical device management system and method Duffin et al. to include the concept of a customized build-to-order software image to a computer system taught by Colligan et al. in order to fit customer's specific needs.

Conclusion

9. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Pirelli (5,611,051) discloses method using a central computer and workstation for managing inventory.

Johnson et al. (5,712,989) discloses a method and system for automatically determined which items in a Just-in-Time inventory are likely to require replenishment.


Linberg (6,385,593 B2) discloses a method and system for remote invoicing and inventory control of medical components of an implantable medical device system.

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lynda C Jasmin whose telephone number is (703) 305-0465. The examiner can normally be reached on Monday- Friday (8:00-5:30) alternate Fridays off.

Art Unit: 3627

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert Olszewski can be reached on (703) 308-5183. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-7687 for regular communications and (703) 305-7687 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 308-1113.


Lynda C. Jasmin
Examiner
Art Unit 3627

lj
October 15, 2002